Work

Development of retinoid nuclear receptor pathway antagonists through targeting aldehyde dehydrogenase 1A3

Year: 2025

Type: article

Abstract: and high-throughput screening approach followed by medicinal optimization to identify first-in-class, oral and safe antagonists of ALDH1A3 with potent anti-tumor immunotherapeutic activity and an optimized drug development profile.

Source: iScience

DOI: 10.1016/j.isci.2025.113675

Authors: Mark Esposito, Cao Fang, Yong Wei, Alfonso Pozzan, Claudia Beato, Xiaoyang Su, Josiah E. Hutton, Tavis Reed, Xiang Hang, Enrico D. Perini, Wen Wang, Xiaobing Cheng, Yan Pan, Jianshi Yu, Maureen Kane, Malini Manoharan, John Proudfoot, Ileana M. Cristea, Yibin Kang

Institutions: Princeton University, Ludwig Cancer Research, Aptuit (Italy), Rutgers, The State University of New Jersey, WuXi AppTec (China), University of Maryland, Baltimore

Language: English

Topic: Synthesis and biological activity

Subfield: Organic Chemistry

Field: Chemistry

Domain: Physical Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,240

Funders: National Science Foundation, American Cancer Society, Breast Cancer Research Foundation, New Jersey Health Foundation, Brewster Foundation, Susan G. Komen, Ludwig Institute for Cancer Research

Award: Graduate Research Fellowship Program (GRFP)

OpenAlex ID: W4414805070

FWCI: 0.876

Cites: 81

Cited by: 3

Related to: